Lonza and Kyowa Hakko extend strategic collaboration
Lonza, of Switzerland, is to license its GS Gene Expression System (GS: glutamine synthetase) to Tokyo-based pharma and biotech company Kyowa Hakko and its US subsidiary BioWa Inc.
Lonza, of Switzerland, is to license its GS Gene Expression System (GS: glutamine synthetase) to Tokyo-based pharma and biotech company Kyowa Hakko and its US subsidiary BioWa Inc.
Prior to this agreement BioWa and Lonza entered into a strategic research collaboration agreement combining Kyowa Hakko's POTELLIGENT technology with Lonza's GS Gene Expression System. This worldwide, non-exclusive umbrella research and licence agreement enables Kyowa Hakko Group to use Lonza's proprietary GS-System and the POTELLIGENT technology as a platform for the production of antibodies and recombinant proteins being developed by Kyowa Hakko Group.
The GS Gene Expression System, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies.
"We are excited about the combination of our POTELLIGENT technology with Lonza's GS Gene Expression System, which has potential to strengthen Kyowa Hakko Group's production system for biological drugs," said Dr Nobuo Hanai, managing officer, head of pharmaceutical r&d division of Kyowa Hakko.
